RxSight
RXST
128 hedge funds and large institutions have $718M invested in RxSight in 2023 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 15 closing their positions.
9,758% more call options, than puts
Call options by funds: $8.48M | Put options by funds: $86K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
53% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 32
13% more capital invested
Capital invested by funds: $637M → $718M (+$81M)
11% more funds holding
Funds holding: 115 → 128 (+13)
7.15% more ownership
Funds ownership: 65.09% → 72.24% (+7.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$16.1M |
| 2 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
+$14.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$14.3M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$10.7M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$9.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$8.82M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.62M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$3.5M |
| 4 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$2.55M |
| 5 |
Millennium Management
New York
|
-$2.16M |
RXST Hedge Fund Activity: Q3 2023 in Review
128 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in RxSight (RXST) for Q3 2023, worth a combined $718M — up 13% from $637M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RXST positions and 15 closed out — a net gain of 13 holders — while 49 added to existing stakes and 32 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $16.1M. The largest seller was Morgan Stanley, cutting an estimated $8.82M.
- 128 institutional investors held RxSight (RXST) as of Q3 2023, up from 115 in Q2 2023.
- Funds reported $718M of RxSight stock for Q3 2023, up 13% quarter-over-quarter.
- 28 funds opened new RxSight positions in Q3 2023 and 15 closed out, a net change of +13 holders.
- The largest RxSight buyer in Q3 2023 was T. Rowe Price Investment Management, an estimated $16.1M added.
- The largest RxSight seller in Q3 2023 was Morgan Stanley, an estimated $8.82M sold.
Based on aggregated 13F filings for Q3 2023.